• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Mavacamten improves function and quality of life in patients with symptomatic hypertrophic obstructive cardiomyopathy

byJessie WillisandTeddy Guo
July 6, 2021
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to placebo, patients treated with mavacamten for 30 weeks showed significant improvements on the KCC Questionnaire which evaluates health status and quality of life.

2. In patients with symptomatic hypertrophic cardiomyopathy, the number needed to treat with mavacamten was 5.

Evidence Rating Level: 2 (Good)

Study Rundown: The EXPLORER-HCM phase III drug trial (2020) found that mavacamten significantly improves patients’ clinical outcomes, such as exercise capacity, NYHA functional class and left ventricular outflow tract (LVOT) obstruction pressure. While these objective measures are essential to document in clinical trials, a patient’s subjective experience and quality of life are also valuable to create a more holistic narrative. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was electronically taken by the patients of EXPLORER-HCM at weeks 6, 12, 18, 30 (end of treatment) and 38 (end of study) of the trial. The KCCQ reports a patient’s quality of life, social and physical function, and burden from their symptoms. Following 30 weeks of treatment, the mavacamten group had a significantly greater increase in KCCQ score compared to the placebo group. A greater proportion of patients on mavacamten showed large improvement on the KCCQ compared to patients given placebo. Additionally, benefits seen with mavacamten sharply diminished after treatment was stopped. Limitations of this study include missing data for 28% of the participants on week 30, due to suspected technical error. Nonetheless, this study provides meaningful information that can be easily communicated to patients when clinicians are considering mavacamten.

Click to read the study in the Lancet

Relevant Reading: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

In-Depth [randomized controlled trial]: This article reports the health status findings of a larger phase III drug trial (EXPLORER-HCM) for mavacamten.  EXPLORER-HCM is a double-blind, randomized control trial in 13 countries between May 30, 2018 to July 12, 2019. Eligibility criteria included adults with LVOT pressure gradients > 50mmHg and NYHA class II-III symptoms. Random assignment was done 1:1 for either mavacamten 5 mg (n=92) or placebo (n=88). EXPLORER-HCM reported on many endpoints, with the primary being clinical benefit (improvement in pVO2 and NYHA class reduction). This study reported on KCCQ-OSS. The 23-item Kansas City Cardiomyopathy Questionnaire evaluates six distinct domains: symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability. It reports two final scores: clinical summary score (CSS) and overall summary (OSS). CSS reports only symptom and physical function, while OSS more holistically includes social and quality of life scores. Participants took this questionnaire electronically before other procedures at weeks 6, 12, 18, 30 (end of treatment), and 38 (end of study, post-medication). KCCQ scores are reported on a scale from 0-100, with 100 being the best.

RELATED REPORTS

Expectant management of patent ductus arteriosus noninferior to early ibuprofen use

Febuxostat may be effective in preventing contrast-induced acute kidney injury

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

At all follow-up points, there was a sustained benefit to KCCQ scores in the mavacamten group (mean score 14.9, [SD 15.8]) compared to the placebo (mean score 5.4 [13.7]; +9.1 increase to mean score at week 30, p<0.0001). Once treatment was stopped at week 38, there was a return to baseline KCCQ score in the mavacamten group with no significant difference between groups (p=0.084). All domains showed this separation between placebo and mavacamten, with physical limitation score being the most effected. In addition, a greater proportion of patients given mavacamten (36%) showed large improvements in KCCQ-OS (≥ 20 points) than placebo (15%; absolute difference = 21%, number needed to treat = 5).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologyCardiomyopathyheart diseasehypertrophic cardiomyopathyleft ventricular outflow tractleft-ventricular outflow tract gradientMavacamtenobstructive hypertrophic myopathy
Previous Post

Neoadjuvant pembrolizumab with chemoradiotherapy not supported for locally advanced rectal cancer after chemotherapy treatment

Next Post

Guideline-concordant multimodal therapy associated with improved mortality outcomes in patients with high-risk prostate cancer

RelatedReports

Wide international variation in survival for periviable neonates
Cardiology

Expectant management of patent ductus arteriosus noninferior to early ibuprofen use

March 30, 2023
Being overweight and obese associated with increased incidence of chronic kidney disease
Cardiology

Febuxostat may be effective in preventing contrast-induced acute kidney injury

March 27, 2023
Cardiac mortality paradoxically lower during times of national cardiology conferences
Cardiology

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

March 24, 2023
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Synergistic interaction between risk burden and genetics for atrial fibrillation development

March 21, 2023
Next Post
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Guideline-concordant multimodal therapy associated with improved mortality outcomes in patients with high-risk prostate cancer

Quick Take: Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study

Rituximab increases sustained complete remission in patients with pemphigus vulgaris

#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma

#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock
  • Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality
  • Childhood maltreatment may cause mental health problems
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options